Young Adult Depression, Antidepressant Prescriptions, and Therapy Intensification in People With Incident Depression in the United States

John Dibato, MSc^a; Olga Montvida, PhD^a; William H. Polonsky, PhD^b; Ken L. Chin, PhD^a,c,d; Sanjoy K. Paul, PhD^a

Prim Care Companion CNS Disord 2022;24(5):21m03162

ABSTRACT

Objective: To evaluate the temporal trend in young adult depression, prescription patterns of first- and second-line antidepressants, and factors influencing therapy intensification for depression stratified by sex.

Methods: A retrospective cohort of people aged ≥ 18 years with incident depression between 2006 and 2017 was extracted from the Centricity Electronic Medical Records.

Results: Among 2,201,086 people with depression (82% on antidepressants), the mean age was 47 years, 29% were male, 40% had cardiometabolic multimorbidity, and 32% were diagnosed at age < 40 years (young adult depression). Prevalence of young adult depression increased significantly from 26% to 36% with a higher proportion in females compared to males (34% vs 26%) between 2006 and 2017. Selective serotonin reuptake inhibitors (SSRIs) were the most prescribed first-line antidepressant (56%), with a prescribing rate increase from 47 per 1,000 person-years to 81 per 1,000 person-years. Among first-line antidepressant recipients, 23% had treatment intensification after a median of 17 months. Compared to those aged 60–70 years, younger males and females had a similar significantly higher treatment intensification risk (range of hazard ratio [HR], 1.09–1.46). Cardiometabolic multimorbidity was associated with a 2% (HR CI, 1.01–1.05) and 7% (HR CI, 1.05–1.09) higher treatment intensification risk in males and females, respectively, while anxiety increased the treatment intensification risk by 63% (HR CI, 1.57–1.68) in males and 57% (HR CI, 1.52–1.62) in females. Non-Whites and SSRI initiators had lower risks of treatment intensification (all HR CI < 1).

Conclusions: More than one-third of US adults with depression are aged < 40 years with an increasing trend among females. The temporal antidepressant prescribing rates were similar between sex, while significant ethnic disparity in therapy intensification was observed between sex

Free Access: Please Log In

This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.

References (43)

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. PubMed CrossRef
Villarroel MA, Terlizzi EP. Symptoms of depression among adults: United States, 2019. NCHS Data Brief. 2020;(379):1–8. PubMed
Brody DJ, Pratt LA, Hughes JP. Prevalence of depression among adults aged 20 and over: United States, 2013–2016. NCHS Data Brief. 2018;(303):1–8. PubMed
Slee A, et al. Trends in generalised anxiety disorders and symptoms in primary care: UK population-based cohort study. Br J Psychiatry. 2021;218(3)158–164. PubMed
Furukawa TA. An epidemic or a plague of common mental disorders? Acta Psychiatr Scand. 2019;140(5):391–392. PubMed CrossRef
Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374(9690):609–619. PubMed CrossRef
Mojtabai R, Olfson M, Han B. National trends in the prevalence and treatment of depression in adolescents and young adults. Pediatrics. 2016;138(6):e20161878. PubMed CrossRef
King DE, Xiang J, Pilkerton CS. Multimorbidity trends in United States adults, 1988–2014. J Am Board Fam Med. 2018;31(4):503–513. PubMed CrossRef
Whitty CJM, MacEwen C, Goddard A, et al. Rising to the challenge of multimorbidity. BMJ. 2020;368:l6964. PubMed CrossRef
National Institute of Mental Health. Strategic Plan for Research 2020. NIMH website. Accessed August 12, 2021. https://www.nimh.nih.gov/sites/default/files/documents/about/strategic-planning-reports/2020_nimh_strategic_plan_508.pdf
Baingana F, al’Absi M, Becker AE, et al. Global research challenges and opportunities for mental health and substance-use disorders. Nature. 2015;527(7578):S172–S177. PubMed CrossRef
Birk JL, Kronish IM, Moise N, et al. Depression and multimorbidity: Considering temporal characteristics of the associations between depression and multiple chronic diseases. Health Psychol. 2019;38(9):802–811. PubMed CrossRef
Hsiao CJ, Dymek C, Kim B, et al. Advancing the use of patient-reported outcomes in practice: understanding challenges, opportunities, and the potential of health information technology. Qual Life Res. 2019;28(6):1575–1583. PubMed CrossRef
American Psychological Association. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. APA website. Accessed August 13, 2021.
Cleare A, Pariante CM, Young AH, et al; Members of the Consensus Meeting. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459–525. PubMed CrossRef
Milea D, Guelfucci F, Bent-Ennakhil N, et al. Antidepressant monotherapy: a claims database analysis of treatment changes and treatment duration. Clin Ther. 2010;32(12):2057–2072. PubMed CrossRef
Kern DM, Cepeda MS, Defalco F, et al. Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019. BMC Psychiatry. 2020;20(1):4. PubMed CrossRef
Gauthier G, Guérin A, Zhdanava M, et al. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis. BMC Psychiatry. 2017;17(1):222. PubMed CrossRef
Castillo EG, Olfson M, Pincus HA, et al. Electronic health records in mental health research: a framework for developing valid research methods. Psychiatr Serv. 2015;66(2):193–196. PubMed CrossRef
Montvida O, Dibato J, Paul S. Evaluating the representativeness of US Centricity Electronic Medical Records with reports from Centers for Disease Control and Prevention: office visits and cardiometabolic conditions. (preprint). JMIR Med Inform. 2020;8(6)e17174. CrossRef
Dibato JE, et al. Association of cardiometabolic multimorbidity and depression with cardiovascular events in early-onset adult type 2 diabetes: a multiethnic study in the US. Diabetes Care. 2021;44(1):231–239. PubMed
Paul SK, Bhatt DL, Montvida O. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study. Eur Heart J. 2021;42(18):1728–1738. PubMed CrossRef
Montvida O, Shaw J, Atherton JJ, et al. Long-term trends in antidiabetes drug usage in the US: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018;41(1):69–78. PubMed CrossRef
Marie Ingram W, et al. Defining major depressive disorder cohorts using the EHR: multiple phenotypes based on ICD-9 codes and medication orders. bioRxiv. 2018:227561.
Deferio JJ, Levin TT, Cukor J, et al. Using electronic health records to characterize prescription patterns: focus on antidepressants in nonpsychiatric outpatient settings. JAMIA Open. 2018;1(2):233–245. PubMed CrossRef
Montvida O, et al. Data mining approach to estimate the duration of drug therapy from longitudinal electronic medical records. Open Bioinform J. 2017;10(1):1–15. CrossRef
Rassen JA, Bartels DB, Schneeweiss S, et al. Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. Clin Epidemiol. 2018;11:1–15. PubMed CrossRef
Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75(4):336–346. PubMed CrossRef
Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Mental Health Findings, NSDUH Series H-42, HHS Publication No. (SMA) 11-4667. Rockville, MD: Substance Abuse and Mental Health Services Administration. 2012. SAMHSA website. Accessed June 26, 2021. https://www.samhsa.gov/data/sites/default/files/2k10MH_Findings/2k10MH_Findings/2k10MHResults.htm#Ch2
Lipari RN. H.S., Hughes A. Substance Use and Mental Health Estimates from the 2013 National Survey on Drug Use and Health: Overview of Findings. 2014 NIH website. Accessed June 27, 2021. https://www.ncbi.nlm.nih.gov/books/NBK385055/
Home CDC. Current Depression Among Adults—United States, 2006 and 2008. CDC website. Accessed June 26, 2021. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5938a2.htm
Centers for Disease Control and Prevention. Mental Illness Surveillance Among Adults in the United States. CDC website. Accessed June 27, 2021. https://www.cdc.gov/mmwr/preview/mmwrhtml/su6003a1.htm
National Cancer Institute. Joinpoint Trend Analysis Software. Surveillance website. Accessed June 27, 2021. https://surveillance.cancer.gov/joinpoint/
Schemper M, Wakounig S, Heinze G. The estimation of average hazard ratios by weighted Cox regression. Stat Med. 2009;28(19):2473–2489. PubMed CrossRef
Li M, Chen S, Lai Y, et al. Integrating real-world evidence in the regulatory decision-making process: a systematic analysis of experiences in the US, EU, and China using a logic model. Front Med (Lausanne). 2021;8:669509. PubMed CrossRef
Department of Health and Human Services. Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01) Clinical Trials Optional. NIH website. Accessed August 14, 2021. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-20-030.html
Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292(3):338–343. PubMed CrossRef
Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry. 2007;164(6):884–891. PubMed CrossRef
Mehta K, Kramer H, Durazo-Arvizu R, et al. Depression in the US population during the time periods surrounding the great recession. J Clin Psychiatry. 2015;76(4):e499–e504. PubMed CrossRef
Moore TJ, Mattison DR. Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med. 2017;177(2):274–275. PubMed CrossRef
Luo Y, et al. National prescription patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015: a population representative survey-based analysis. Front Psychiatry. 2020;11(35):fpsyt.2020.00035.
Rush AJ, Trivedi MH, Wisniewski SR, et al; STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231–1242. PubMed CrossRef
Rowan CG, Flory J, Gerhard T, et al. Agreement and validity of electronic health record prescribing data relative to pharmacy claims data: a validation study from a US electronic health record database. Pharmacoepidemiol Drug Saf. 2017;26(8):963–972. PubMed CrossRef